Leap Therapeutics Faces Delisting Concerns

TL;DR

LEAP might get delisted, check exchange rules.

AI Summary

Leap Therapeutics, Inc. filed an 8-K on September 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on September 10, 2025. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.

Why It Matters

This filing indicates potential issues with Leap Therapeutics' compliance with stock exchange listing requirements, which could lead to the stock being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and future viability.

Key Players & Entities

• Leap Therapeutics, Inc. (company) — Registrant
• September 10, 2025 (date) — Earliest event reported
• September 11, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Cambridge, MA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
• $1.00 — common stock has been below the minimum $1.00 per share required for continued listin

Filing Documents

• tm2525891d1_8k.htm (8-K) — 28KB
• 0001410578-25-002072.txt ( ) — 189KB
• lptx-20250910.xsd (EX-101.SCH) — 3KB
• lptx-20250910_lab.xml (EX-101.LAB) — 33KB
• lptx-20250910_pre.xml (EX-101.PRE) — 22KB
• tm2525891d1_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on March 12, 2025, Leap Therapeutics, Inc. (the "Company") received a notification letter (the "Closing Bid Price Deficiency Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, based on the previous 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). The Company had 180 days, or until September 8, 2025, to regain compliance with Rule 5550(a)(2) by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Additionally, Nasdaq notified the Company that it might be eligible for an additional compliance period of 180 calendar days if, on September 8, 2025, the Company met the continued listing requirement for market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital Market (with the exception of the closing bid price requirement) based on the Company's then most recent public filings and market information, and the Company provided written notice to Nasdaq of its intent to cure during such additional compliance period of 180 calendar days the deficiency in the Company's compliance with the minimum closing bid price requirement of Rule 5550(a)(2), including, without limitation, by effecting a reverse stock split, if necessary. On September 2, 2025, the Company submitted a request to Nasdaq for an additional 180 calendar day period to regain compliance with the minimum bid price requirement and gave notice of its intention to cure the deficiency during the second compliance period by effecting a reverse split, if necessary. On September 10, 2025, the Company received a let

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: September 11, 2025 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: President & CEO

View Full Filing

View this 8-K filing on SEC EDGAR